Abstract:The high prevalence of hypertension in China is well known, with stroke being the most common cause of death and disability. 1 GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385: 117-171 Summary Full Text Full Text PDF PubMed Scopus (5370) Google Scholar Two large nationwide studies reported in The Lancet2 Lu J Lu Y Wang X et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017; (published online Oct 25.)http://dx.doi.org/10.1016/S0140-6736(17)32478-9 Summary Full Text Full Text PDF Scopus (567) Google Scholar , 3 Su M Zhang Q Bai X et al. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet. 2017; (published online Oct 25.)http://dx.doi.org/10.1016/S0140-6736(17)32476-5 Summary Full Text Full Text PDF Scopus (82) Google Scholar highlight that although the prevalence of hypertension in China is similar to that suggested in previous studies, it is simple deficiencies in the country's health system that make a large contribution to the disease burden. Both studies used data from the PEACE (Patient-Centred Evaluative Assessment of Cardiac Events) Million Persons Project (MPP), which enrolled 1·7 million adults aged 35–75 years from across China. This is a population-centred, national screening initiative to detect populations at high risk of cardiovascular disease. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project)Among Chinese adults aged 35–75 years, nearly half have hypertension, fewer than a third are being treated, and fewer than one in twelve are in control of their blood pressure. The low number of people in control is ubiquitous in all subgroups of the Chinese population and warrants broad-based, global strategy, such as greater efforts in prevention, as well as better screening and more effective and affordable treatment. Full-Text PDF Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional surveyChina has marked deficiencies in the availability, cost, and prescription of antihypertensive medications. High-value medications are not preferentially used. Future efforts to reduce the burden of hypertension, particularly through the work of primary health-care providers, will need to improve access to, and use of, antihypertensive medications, paying particular attention to those with high value. Full-Text PDF

The interpretation of new hypertension guidelines

Editors' Commentary on the 2023 ESH Management of Arterial Hypertension Guidelines

Comparative Analysis of Hypertension Guidelines: Unveiling Consensus and Discrepancies in Lifestyle Modifications for Blood Pressure Control

Highlights of the 2018 Chinese hypertension guidelines

Updated National and International Hypertension Guidelines: A Review of Current Recommendations

Interpretation for“2014 evidence-based guideline for the management of high blood pressure in adults”in the United States:discussion of the rational treatment of hypertension

What is New in the ESC Hypertension Guideline?

Clinical practice guidelines for the management of hypertension in China

Guideline-Driven Management of Hypertension: An Evidence-Based Update

Why were the 2023 Guidelines of the European Society of Hypertension not developed as Joint Guidelines together with the European Society of Cardiology?

Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines

Prevalence and Treatment of Hypertension in China: Impacts of 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline.

Appropriateness of the 2017 ACC/AHA Guidelines: Applied to Data from the China National Stroke Screening and Prevention Project Study

A comprehensive overview of the diagnosis and treatment of hypertension based on the latest hypertension guidelines

The Rates and the Determinants of Hypertension According to the 2017 Definition of Hypertension by ACC/AHA and 2014 Evidence-Based Guidelines Among Population Aged ≥40 Years Old

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)

The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension

Abstract P205: Potential Impact of the 2014 High Blood Pressure Guideline on Adults in China and the US

Impact of 2017 ACC/AHA guidelines on prevalence of hypertension and eligibility for antihypertensive treatment in United States and China: nationally representative cross sectional study

A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension

Hypertension in China: the Gap Between Policy and Practice